Methotrexate disodium
Based on 80 publication(s) in Google Scholar
Methotrexate (Amethopterin) disodium, an antimetabolite and antifolate agent, inhibits the enzyme dihydrofolate reductase, thereby preventing the conversion of folic acid into tetrahydrofolate, and inhibiting DNA synthesis. Methotrexate disodium, also an immunosuppressant and antineoplastic agent, is used for the research of rheumatoid arthritis and a number of different cancers (such as acute lymphoblastic leukemia).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.63%
- CAS No.: 7413-34-5
- Formule: C20H20N8Na2O5
- Masse moléculaire:498.40
-
Stockage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Toxins for Antibody-Drug Conjugate Research Library
HY-L023
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Immunology/Inflammation Compound Library
HY-L007
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Antibacterial Compound Library
HY-L049
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Rare Diseases Drug Library
HY-L102
-
Pediatric Drug Library
HY-L104
-
Chemotherapy Drug Library
HY-L112
-
EMA-Approved Drug Library
HY-L116
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Non-steroidal Anti-Inflammatory Compound Library
HY-L130
-
Heterocyclic Compound Library
HY-L138
-
Off-patent Drug Library
HY-L141
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
RNA Binding Bioactive Compound Library
HY-L248
Publications Citing Use of MedChemExpress (MCE) Methotrexate disodium
More- Mol Cancer. 2024 Apr 29;23(1):86. [Abstract]
- Mol Cancer. 2024 Jan 10;23(1):12. [Abstract]
- Adv Mater. 2025 Dec 12:e13952. [Abstract]
- Adv Mater. 2025 Jul 4:e2505231. [Abstract]
- Nat Commun. 2025 Feb 28;16(1):2071. [Abstract]
- J Clin Invest. 2023 Jul 3;133(13):e169993. [Abstract]
- J Adv Res. 2025 Aug:74:609-620. [Abstract]
- J Exp Clin Cancer Res. 2024 Dec 26;43(1):330. [Abstract]
- J Nanobiotechnology. 2024 Mar 3;22(1):89. [Abstract]
- Small. 2022 Jul;18(30):e2202337. [Abstract]
- Redox Biol. 2024 Dec 25:79:103482. [Abstract]
- Cell Rep Med. 2025 Apr 2:102053. [Abstract]
- Mol Biomed. 2025 Nov 21;6(1):114. [Abstract]
- Cell Death Dis. 2025 Nov 24;16(1):852. [Abstract]
- Cell Death Dis. 2025 Nov 24;16(1):856. [Abstract]
- Acta Biomater. 2025 Aug 27:S1742-7061(25)00640-3. [Abstract]
- Biomater Res. 2025 Sep 3:29:0245. [Abstract]
- Cell Death Dis. 2024 May 20;15(5):349. [Abstract]
- Cell Death Dis. 2020 Nov 12;11(11):976. [Abstract]
- J Pharm Anal. 2022 Dec;12(6):879-888. [Abstract]
- Acta Pharmacol Sin. 2025 Jun;46(6):1733-1741. [Abstract]
- Acta Pharmacol Sin. 2021 Jan;42(1):108-114. [Abstract]
- Phytomedicine. 2025 Dec 19:150:157731. [Abstract]
- EMBO Mol Med. 2025 Oct 13. [Abstract]
- Phytomedicine. 2022 Jun;100:154068. [Abstract]
- EMBO Mol Med. 2022 Mar 7;14(3):e14552. [Abstract]
- Biomed Pharmacother. 2024 Jul 19:178:117167. [Abstract]
- Cell Rep. 2025 Mar 25;44(4):115466. [Abstract]
- Sci Data. 2024 Sep 19;11(1):1024. [Abstract]
- Sci Signal. 2024 Nov 26;17(864):eadp1375. [Abstract]
- Ecotoxicol Environ Saf. 2025 Nov 15:307:119433. [Abstract]
- J Ethnopharmacol. 2026 Apr 24:361:121230. [Abstract]
- Cells. 2026 Jun 11;15(12):1070. [Abstract]
- Commun Biol. 2022 Jun 23;5(1):619. [Abstract]
- Eur J Pharm Sci. 2025 Sep 27:214:107296. [Abstract]
- Int Immunopharmacol. 2025 May 23:159:114894. [Abstract]
- Int Immunopharmacol. 2025 Apr 26:156:114735. [Abstract]
- Int Immunopharmacol. 2024 Jun 15:134:112183. [Abstract]
- Int Immunopharmacol. 2023 Nov 15;125(Pt B):111175. [Abstract]
- Eur J Pharmacol. 2023 Dec 15:961:176162. [Abstract]
- Int Immunopharmacol. 2023 Feb:115:109689. [Abstract]
- Arthritis Res Ther. 2022 Jan 19;24(1):27. [Abstract]
- Toxicology. 2020 May 15;437:152445. [Abstract]
- Antimicrob Agents Chemother. 2026 Jul;70(7):e0196025. [Abstract]
- Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
- Rheumatology (Oxford). 2025 Aug 13:keaf437. [Abstract]
- Cancers (Basel). 2022 Oct 19;14(20):5127. [Abstract]
- Cancers. 2019 Oct 25;11(11):1654. [Abstract]
- ACS Omega. 2026 Jan 21;11(4):5853-5864. [Abstract]
- ACS Omega. 2025 Oct 29;10(44):52562-52575. [Abstract]
- J Cell Mol Med. 2026 Apr;30(7):e71101. [Abstract]
- Mediators Inflamm. 2024 Dec 5:2024:1995952. [Abstract]
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- Antiviral Res. 2026 Jun:250:106417. [Abstract]
- Lung. 2024 Nov 27;203(1):4. [Abstract]
- Sci Rep. 2024 Oct 31;14(1):26224. [Abstract]
- J Biol Chem. 2019 Dec 27;294(52):20084-20096. [Abstract]
- Sci Rep. 2018 Jun 21;8(1):9472. [Abstract]
- Chem Res Toxicol. 2025 Feb 17;38(2):281-295. [Abstract]
- Biotechnol Bioeng. 2021 Dec;118(12):4687-4698. [Abstract]
- J Bone Oncol. 2021 Sep 20:30:100391. [Abstract]
- Dis Model Mech. 2023 Mar 1;16(3):dmm049769. [Abstract]
- Mol Immunol. 2025 Apr 16:182:83-95. [Abstract]
- Micromachines. 2021 Jun 10;12(6):681. [Abstract]
- Plasma Process Polym. 2021 Feb 12.
- Int J Immunopathol Pharmacol. 2025 Jan-Dec:39:3946320251348715. [Abstract]
- Biochem Biophys Rep. 2021 Nov 26:28:101177. [Abstract]
- Anticancer Res. 2024 Oct;44(10):4213-4218. [Abstract]
- Anticancer Res. 2024 Jul;44(7):2787-2792. [Abstract]
- bioRxiv. 2026 May 6.
- bioRxiv. 2025 Nov 20.
- SSRN. 2025 Oct 10.
- Patent. US20250235423A1.
- Authorea. 2025 Jan 03.
- Guidelines and Standards in Chinese Medicine. 2024 Dec.
- Research Square Preprint. 2023 Dec 4.
- Research Square Preprint. 2023 Dec 1.
- Queen’s University. 2021 Oct.
- Oncotarget. 2017 Dec 2;8(68):112313-112329. [Abstract]
- Patent. US20170128439A1.
Customer Validation & Images
-
Cell Imaging/Staining
-
RT-PCR
-
Cell Proliferation/Viability Assay
-
Cell Migration/Invasion Assay
-
Cell Proliferation/Viability Assay
Voir tous les produits spécifiques à Isoform DNA/RNA Synthesis
MoreVoir tous les produits spécifiques à Isoform ADC Payloads
More
Activité biologique
|
Traditional Cytotoxic Agents |
Methotrexate (MTX) disodium (2 mg/kg; i.p.; once in a week for 5 weeks) is effective in Freund's complete adjuvant-induced arthritis. The combination of Methotrexate disodium (1 mg/kg; i.p.; once in a week for 5 weeks) and Curcumin (30 mg/kg and 100 mg/kg, thrice a week for 5 weeks; i.p.) shows a significant anti-arthritic action and protection from hematological toxicity[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 7413-34-5
-
Appearance Solid
-
Masse moléculaire 498.40
-
Formule C20H20N8Na2O5
-
Color Light yellow to yellow
-
SMILES
NC1=NC(N)=C2C(N=CC(CN(C)C3=CC=C(C(N[C@@H](CCC(O[Na])=O)C(O[Na])=O)=O)C=C3)=N2)=N1
-
Synonyms
Amethopterin disodium; CL14377 disodium; WR19039 disodium
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (80)
-
Journal Impact Factor
-
Most Recent
-
Mol Cancer
2024 Apr 29;23(1):86. PMID: 38685067 -
Mol Cancer
Organoids derived from patients provide a new opportunity for research and individualized treatment of malignant peritoneal mesothelioma. [Abstract]2024 Jan 10;23(1):12. PMID: 38200517 -
Adv Mater
3D Bioprinted Human Synovium-Cartilage Models Mimic Rheumatoid Arthritis Microenvironment and Recapitulate In Vivo Therapeutic Responses. [Abstract]2025 Dec 12:e13952. PMID: 41388589 -
Adv Mater
Soft Extrudable Dendritic Particles with Nanostructured Tendrils for Local Adhesion and Drug Release to Bladder Cancers. [Abstract]2025 Jul 4:e2505231. PMID: 40611758 -
Nat Commun
ACSS2 drives senescence-associated secretory phenotype by limiting purine biosynthesis through PAICS acetylation. [Abstract]2025 Feb 28;16(1):2071. PMID: 40021646
Methotrexate disodium purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 28;16(1):2071. [Abstract]
OIS cells were infected with shCtrl orshACSS2 followed by selection and treated with or without MTX (40 μM) for 2 days. Cells were stained with γH2AX.
Methotrexate disodium purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 28;16(1):2071. [Abstract]
OIS cells were infected with shCtrl orshACSS2 followed by selection and treated with or without MTX (40 μM) for 2 days. The expression of SASP genes was analysed by qRT–PCR.
-
J Clin Invest
Therapeutic targeting of metabolic vulnerabilities in cancers with MLL3/4-COMPASS epigenetic regulator mutations. [Abstract]2023 Jul 3;133(13):e169993. PMID: 37252797
Methotrexate disodium purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2023 Jul 3;133(13):e169993. [Abstract]
A CellTiter-Glo® luminescent cell viability assay was performed on CAL51 WT and MLL4 KO cells, which were treated with 0, 0.04, or 0.4 μM Methotrexate (MTX) in the presence of H2O, 50 μM thymidine, or 50 μM inosine.
-
J Adv Res
Columbianadin ameliorates rheumatoid arthritis by attenuating synoviocyte hyperplasia through targeted vimentin to inhibit the VAV2/Rac-1 signaling pathway. [Abstract]2025 Aug:74:609-620. PMID: 39369957
Methotrexate disodium purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Aug:74:609-620. [Abstract]
The cell viability of MH7A cells treated with methotrexate (1 μM) for 24 h was determined by the CCK-8 method.
Methotrexate disodium purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Aug:74:609-620. [Abstract]
The cell migration of MH7A cells treated with methotrexate (1 μM) for 24 h.
-
J Exp Clin Cancer Res
OTULIN confers cisplatin resistance in osteosarcoma by mediating GPX4 protein homeostasis to evade the mitochondrial apoptotic pathway. [Abstract]2024 Dec 26;43(1):330. PMID: 39721999 -
J Nanobiotechnology
EphA2-specific microvesicles derived from tumor cells facilitate the targeted delivery of chemotherapeutic drugs for osteosarcoma therapy. [Abstract]2024 Mar 3;22(1):89. PMID: 38433190 -
Small
DNA Base Pairing-Inspired Supramolecular Nanodrug Camouflaged by Cancer-Cell Membrane for Osteosarcoma Treatment. [Abstract]2022 Jul;18(30):e2202337. PMID: 35780479 -
Redox Biol
Therapeutic potential of monomethyl fumarate and aluminum ion combination in alleviating inflammation and oxidative stress in psoriasis. [Abstract]2024 Dec 25:79:103482. PMID: 39736200 -
Cell Rep Med
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]2025 Apr 2:102053. PMID: 40187357 -
Mol Biomed
A single non-coding SNP in FPGS modulates folate drug efficacy in acute lymphoblastic leukemia: data-driven exploration and experimental validation. [Abstract]2025 Nov 21;6(1):114. PMID: 41269429 -
Cell Death Dis
Downregulation of ZFP36L1 contributes to methotrexate resistance in osteosarcoma through enhanced NHEJ DNA repair mechanisms. [Abstract]2025 Nov 24;16(1):852. PMID: 41285712 -
Cell Death Dis
2025 Nov 24;16(1):856. PMID: 41285805 -
Acta Biomater
2025 Aug 27:S1742-7061(25)00640-3. PMID: 40882907 -
Biomater Res
Albumin Nanocages with Methotrexate and Chondroitin Sulfate as a Dual pH/GSH-Responsive Tumor Targeting Nanomedicine for Synergistic Cancer Therapy. [Abstract]2025 Sep 3:29:0245. PMID: 40908968 -
Cell Death Dis
Deprivation of methionine inhibits osteosarcoma growth and metastasis via C1orf112-mediated regulation of mitochondrial functions. [Abstract]2024 May 20;15(5):349. PMID: 38769167 -
Cell Death Dis
2020 Nov 12;11(11):976. PMID: 33184290 -
J Pharm Anal
A highly efficient protein corona-based proteomic analysis strategy for the discovery of pharmacodynamic biomarkers. [Abstract]2022 Dec;12(6):879-888. PMID: 36605576 -
Acta Pharmacol Sin
Bardoxolone displays potent activity against triple negative breast cancer by inhibiting the TRIP13/STAT3 circuit. [Abstract]2025 Jun;46(6):1733-1741. PMID: 39939802 -
Acta Pharmacol Sin
Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. [Abstract]2021 Jan;42(1):108-114. PMID: 32398685 -
Phytomedicine
Paeoniflorin derivative ameliorates methotrexate resistance in treating rheumatoid arthritis through targeting GRK2-A2AAR axis. [Abstract]2025 Dec 19:150:157731. PMID: 41447845 -
EMBO Mol Med
Glycine decarboxylase advances IgA nephropathy by boosting mesangial cell proliferation through the pyrimidine pathway. [Abstract]2025 Oct 13. PMID: 41083822 -
Phytomedicine
Geniposide alleviates VEGF-induced angiogenesis by inhibiting VEGFR2/PKC/ERK1/2-mediated SphK1 translocation. [Abstract]2022 Jun;100:154068. PMID: 35358930 -
EMBO Mol Med
A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis. [Abstract]2022 Mar 7;14(3):e14552. PMID: 35174975 -
Biomed Pharmacother
Characterization of a deazaflavin analog as a potent inhibitor of multidrug resistance-associated protein 1. [Abstract]2024 Jul 19:178:117167. PMID: 39032285 -
Cell Rep
Structural basis for the reversal of human MRP4-mediated multidrug resistance by lapatinib. [Abstract]2025 Mar 25;44(4):115466. PMID: 40138312 -
Sci Data
High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma. [Abstract]2024 Sep 19;11(1):1024. PMID: 39300112 -
Sci Signal
Coordination between the eIF2 kinase GCN2 and p53 signaling supports purine metabolism and the progression of prostate cancer. [Abstract]2024 Nov 26;17(864):eadp1375. PMID: 39591412 -
Ecotoxicol Environ Saf
PPARγ-responsive luciferase reporter system for high-throughput screening of chemical toxins with potential pulmonary fibrosis effects. [Abstract]2025 Nov 15:307:119433. PMID: 41273832 -
J Ethnopharmacol
Kai-Xin-San alleviates Alzheimer's disease by targeting the DHFR-mediated folate-mitochondrial axis. [Abstract]2026 Apr 24:361:121230. PMID: 41548619 -
Cells
Structure-Based Virtual Screening and Mechanistic Characterization of Methotrexate and Selinexor as Potent Anti-Melanogenic Agents via Multi-Pathway Suppression of MITF. [Abstract]2026 Jun 11;15(12):1070. PMID: 42346097 -
Commun Biol
Serine hydroxymethyltransferase as a potential target of antibacterial agents acting synergistically with one-carbon metabolism-related inhibitors. [Abstract]2022 Jun 23;5(1):619. PMID: 35739195 -
Eur J Pharm Sci
Repurposing of FDA-approved drugs by targeting SIRT2 to alleviate inflammatory response and kidney injury. [Abstract]2025 Sep 27:214:107296. PMID: 41022315 -
Int Immunopharmacol
Isorhapontigenin suppresses inflammation, proliferation and aggressiveness of rheumatoid arthritis fibroblast-like synoviocytes by targeting farnesyl diphosphate synthase. [Abstract]2025 May 23:159:114894. PMID: 40412131 -
Int Immunopharmacol
Regulation of P-glycoprotein through CaMKII/cPLA2 pathway in lymphocytes for treating refractory rheumatoid arthritis by manidipine. [Abstract]2025 Apr 26:156:114735. PMID: 40294472 -
Int Immunopharmacol
Cornuside alleviates psoriasis-like skin lesions in mice by relieving inflammatory effects. [Abstract]2024 Jun 15:134:112183. PMID: 38705031 -
Int Immunopharmacol
Herbal compound cepharanthine attenuates inflammatory arthritis by blocking macrophage M1 polarization. [Abstract]2023 Nov 15;125(Pt B):111175. PMID: 37976601 -
Eur J Pharmacol
Lycorine eliminates B-cell acute lymphoblastic leukemia cells by targeting PSAT1 through the serine/glycine metabolic pathway. [Abstract]2023 Dec 15:961:176162. PMID: 37951487 -
Int Immunopharmacol
Iso-seco-tanapartholide induces p62 covalent oligomerization to activate KEAP1-NRF2 redox pathway in rheumatoid arthritis. [Abstract]2023 Feb:115:109689. PMID: 36621330 -
Arthritis Res Ther
Penfluridol targets acid sphingomyelinase to inhibit TNF signaling and is therapeutic against inflammatory autoimmune diseases. [Abstract]2022 Jan 19;24(1):27. PMID: 35045889 -
Toxicology
Drug interaction study of flavonoids toward OATP1B1 and their 3D structure activity relationship analysis for predicting hepatoprotective effects. [Abstract]2020 May 15;437:152445. PMID: 32259555 -
Antimicrob Agents Chemother
Pralatrexate is a potent pan-serotype human adenovirus inhibitor through suppression of dihydrofolate reductase. [Abstract]2026 Jul;70(7):e0196025. PMID: 42206914 -
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
Rheumatology (Oxford)
Autophagy inhibitors block pathogenic NET release in immune-mediated inflammatory disease without impairing host defence. [Abstract]2025 Aug 13:keaf437. PMID: 40802538 -
Cancers (Basel)
Association between Dysfunction of the Nucleolar Stress Response and Multidrug Resistance in Pediatric Acute Lymphoblastic Leukemia. [Abstract]2022 Oct 19;14(20):5127. PMID: 36291909 -
Cancers
2019 Oct 25;11(11):1654. PMID: 31717700 -
ACS Omega
ROS-Scavenging Bamboo-Derived Carbon Dot-Methotrexate Nanocomposite Ameliorates Rheumatoid Arthritis through Dual Therapeutic Mechanisms. [Abstract]2026 Jan 21;11(4):5853-5864. PMID: 41658163 -
ACS Omega
Association Study of OATP1B3 Polymorphisms on Hepatic Uptake and Drug-Drug Interaction In Vitro. [Abstract]2025 Oct 29;10(44):52562-52575. PMID: 41244417 -
J Cell Mol Med
2026 Apr;30(7):e71101. PMID: 41896195 -
Mediators Inflamm
Peptide BG From Bitter Gourd (Momordica Charantia) Improves Adjuvant-Induced Arthritis by Modulating the Necroptosis/Neutrophil Extracellular Traps/Inflammation Axis and the Gut Microbiota. [Abstract]2024 Dec 5:2024:1995952. PMID: 39669913 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
Antiviral Res
Repurposing screen using a robust human rhinovirus infectious clone identifies pyrvinium pamoate with antiviral activity. [Abstract]2026 Jun:250:106417. PMID: 42025967 -
Lung
Disulfiram Alleviates MTX-Induced Pulmonary Fibrosis by Inhibiting EMT in Type 2 Alveolar Epithelial Cells. [Abstract]2024 Nov 27;203(1):4. PMID: 39601871 -
Sci Rep
High expression of LncRNA HOTAIR is a risk factor for temozolomide resistance in glioblastoma via activation of the miR-214/β-catenin/MGMT pathway. [Abstract]2024 Oct 31;14(1):26224. PMID: 39482401 -
J Biol Chem
A technique for delineating the unfolding requirements for substrate entry into retrotranslocons during endoplasmic reticulum-associated degradation. [Abstract]2019 Dec 27;294(52):20084-20096. PMID: 31748412 -
Sci Rep
A widely-applicable high-throughput cellular thermal shift assay (CETSA) using split Nano Luciferase. [Abstract]2018 Jun 21;8(1):9472. PMID: 29930256 -
Chem Res Toxicol
Inhibitory Effects of Alkaloids on OATP1B1 In Vitro and In Vivo: Prediction for Food/Herb-Drug Interactions and Hepatoprotective Effects Based on Structure-Activity Relationships. [Abstract]2025 Feb 17;38(2):281-295. PMID: 39899883 -
Biotechnol Bioeng
An integrated biomimetic array chip for establishment of collagen-based 3D primary human hepatocyte model for prediction of clinical drug-induced liver injury. [Abstract]2021 Dec;118(12):4687-4698. PMID: 34478150 -
J Bone Oncol
Identification of GPC3 mutation and upregulation in a multidrug resistant osteosarcoma and its spheroids as therapeutic target. [Abstract]2021 Sep 20:30:100391. PMID: 34611509 -
Dis Model Mech
A Drosophila chemical screen reveals targeting MEK and DGKa mitigates Ras-driven polarity-impaired tumour growth. [Abstract]2023 Mar 1;16(3):dmm049769. PMID: 36861754 -
Mol Immunol
Methotrexate loaded extracellular vesicles attenuate periodontitis by suppressing ACSL1 and promoting anti-inflammatory macrophage. [Abstract]2025 Apr 16:182:83-95. PMID: 40245705 -
Micromachines
2021 Jun 10;12(6):681. PMID: 34200752 -
-
Int J Immunopathol Pharmacol
Cucurbitacin B inhibits Th17 cell differentiation via the suppression of the JAK/STAT pathway and alleviates collagen-induced arthritis in mice. [Abstract]2025 Jan-Dec:39:3946320251348715. PMID: 40518910 -
Biochem Biophys Rep
Histone H3 lysine-trimethylation markers are decreased by recombinant methioninase and increased by methotrexate at concentrations which inhibit methionine-addicted osteosarcoma cell proliferation. [Abstract]2021 Nov 26:28:101177. PMID: 34877414 -
Anticancer Res
Loss of Malignancy of Super-Methotrexate-resistant Osteosarcoma Cells Is Associated With an Increase of Methylated Histone Marks H3K9me3 and H3K27me3. [Abstract]2024 Oct;44(10):4213-4218. PMID: 39348992 -
Anticancer Res
Reduced Malignancy of Super Methotrexate-resistant Osteosarcoma Cells With Dihydrofolate Reductase Amplification Despite Paradoxical Gain of Oncogenic PI3K/AKT/mTOR and c-MYC expression. [Abstract]2024 Jul;44(7):2787-2792. PMID: 38925854 -
-
-
-
-
-
-
-
-
-
Oncotarget
Molecular-genetic profiling and high-throughput in vitro drug screening in NUT midline carcinoma-an aggressive and fatal disease. [Abstract]2017 Dec 2;8(68):112313-112329. PMID: 29348827 -
Solvant et solubilité
H2O : 50 mg/mL (100.32 mM; Need ultrasonic)
DMSO : 5 mg/mL (10.03 mM; ultrasonic and warming and adjust pH to 5 with HCl and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (274 KB)
-
SDS (421 KB)
- English - EN (421 KB)
- Français - FR (421 KB)
- Deutsch - DE (421 KB)
- Norwegian - NO (421 KB)
- Español - ES (421 KB)
- Swedish - SV (421 KB)
- Italian - IT (421 KB)
- Korean - KR (421 KB)
- Portuguese - PT (421 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Tian H, et al. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65(3):168-73. [Content Brief]
[2]. Swierkot J, et al. Methotrexate in rheumatoid arthritis. Pharmacol Rep. 2006 Jul-Aug;58(4):473-92. [Content Brief]
[3]. Swierkot J, et al. Methotrexate in rheumatoid arthritis. Pharmacol Rep. 2006 Jul-Aug;58(4):473-92.
[4]. Banji D, et al. Evaluation of the concomitant use of methotrexate and curcumin on Freund's complete adjuvant-induced arthritis and hematological indices in rats. Indian J Pharmacol. 2011;43(5):546-550. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 2.0064 mL | 10.0321 mL | 20.0642 mL | 50.1605 mL |
| 5 mM | 0.4013 mL | 2.0064 mL | 4.0128 mL | 10.0321 mL | |
| 10 mM | 0.2006 mL | 1.0032 mL | 2.0064 mL | 5.0161 mL | |
| H2O | 15 mM | 0.1338 mL | 0.6688 mL | 1.3376 mL | 3.3440 mL |
| 20 mM | 0.1003 mL | 0.5016 mL | 1.0032 mL | 2.5080 mL | |
| 25 mM | 0.0803 mL | 0.4013 mL | 0.8026 mL | 2.0064 mL | |
| 30 mM | 0.0669 mL | 0.3344 mL | 0.6688 mL | 1.6720 mL | |
| 40 mM | 0.0502 mL | 0.2508 mL | 0.5016 mL | 1.2540 mL | |
| 50 mM | 0.0401 mL | 0.2006 mL | 0.4013 mL | 1.0032 mL | |
| 60 mM | 0.0334 mL | 0.1672 mL | 0.3344 mL | 0.8360 mL | |
| 80 mM | 0.0251 mL | 0.1254 mL | 0.2508 mL | 0.6270 mL | |
| 100 mM | 0.0201 mL | 0.1003 mL | 0.2006 mL | 0.5016 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Methotrexate disodium Related Classifications
HY-14519A Related Classifications
Powered by Bioz